SET2,3 to inform on chemotherapy decisions in ER-positive breast cancer Presented ByDr Otto Metzger, Dana-Farber Cancer Institute, MA, USA TrialPhase 3, CALGB9741 ConferenceASCO 2022 5 August, 2022 11:59